Catalyst Wire Dossier Catalyst Wire Dossier
EMA withdrawal · 2008-05-23

EMA Application withdrawn: orBec (beclomethasone dipropionate) — DOR BIOPHARMA UK Ltd

View source ↗

Summary

The EMA withdrew the application for orBec (beclomethasone dipropionate) for graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • orBec (beclomethasone dipropionate)

Snippet

Status: Application withdrawn. Therapeutic area: Graft vs Host Disease. MAH: DOR BIOPHARMA UK Ltd. Decision date: 31/12/2009. Orphan medicine